Tushar Arora

The GMP Insider

GMP Insider is your go-to podcast for practical insights into pharmaceutical quality, Good Manufacturing Practices (GMP), and regulatory compliance. Designed for quality professionals, manufacturing teams, and pharma leaders, this show breaks down complex regulations into clear, real-world guidance. Each episode explores topics like audits, CAPA, data integrity, quality systems, validation, and global regulatory expectations — all with a focus on protecting patients and building strong quality cultures. Whether you work in Quality Assurance, Quality Control, Manufacturing, or Regulatory Affair...

No dejes de visitar la web del podcast y apoyar a su creador: www.podserve.fm

Autor

Tushar Arora

Categoría

Science

Web del podcast

www.podserve.fm

Último episodio

18 de nov. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android 10 M+ de descargas · valoración de 4,7+ iOS muy pronto

Episodios

Cleaning Validation: Worst-Case Approach, PDE and MACO Limits 18.11.2026

Cleaning validation fails in places nobody looked: the product nobody chose, the limit nobody calculated, the swab nobody recovered. Marcus and Priya work through the modern approach — worst-case product selection argued on paper, health-based PDE limits replacing inherited rules of thumb, the MACO carryover calculation step by step, and the sampling, recovery, and hold-time science that makes the...

Environmental Monitoring: Alert vs Action Limits & Trending 16.11.2026

An environmental monitoring programme can collect data for a year and still know nothing — thousands of results, beautifully filed, never trended, never questioned. Marcus and Priya lay out EM done properly: alert limits built from your own baseline, trending by location, organism and operator, excursion investigations that separate the batch decision from the root-cause hunt, and the findings ins...

ICH Q9(R1) Quality Risk Management: What's Actually New 11.11.2026

Most quality risk assessments fail in the first ten minutes, when someone picks a score out of the air and the room nods. Marcus and Priya break down what the ICH Q9(R1) revision actually changed: formality that follows risk, subjectivity named and managed as a bias problem, product availability as a new risk lens, and risk review that turns assessments into living records instead of souvenirs. •...

Change Control Management: What Gets Companies in Trouble 09.11.2026

The most dangerous change in a GMP plant is not the big capital project everyone debates for a year — it is the small one nobody logged, because someone called it like for like. Marcus and Priya walk through change control management: what the system is actually for, the invisible changes that escape it, where impact and risk assessment do the real work, the timing failures inspectors cite, honest...

Contamination Control Strategy (CCS) Under EU GMP Annex 1 04.11.2026

Most contamination control strategies fail on page one — not because anything in them is wrong, but because everything in them is copied from somewhere else. Marcus and Priya break down the CCS under EU GMP Annex 1: what it actually has to contain, how facility design, people, sterilisation, media fills, monitoring, and disinfection connect into one risk-based argument, the five failure patterns i...

Deviation Investigation & Root Cause Analysis: 5 Whys Done Right 02.11.2026

Most deviation investigations fail not because teams pick the wrong tool, but because they stop asking why the moment the answer becomes uncomfortable — usually at "human error" and a retraining record. Marcus and Priya walk through a real investigation: containment and timeline reconstruction in the first hours, the 5 Whys worked step by step on evidence, where the tool breaks, the fishbone bread...

How to Respond to an FDA 483 (and Warning Letter) in 15 Working Days 28.10.2026

The inspection is over — and the second half of it has just started. Your written response to a Form FDA 483 is due within 15 working days, and FDA weighs it before deciding whether the matter ends there or escalates to a Warning Letter. Marcus and Priya lay out the full 15-day playbook: what a 483 is and is not, day-one triage and ownership, extent-of-condition review, root cause and CAPA discipl...

FDA Inspection Readiness 2026: The New Cross-System Inspection Model 26.10.2026

FDA doesn't inspect your quality systems in silos anymore. The new inspection model is hypothesis-driven: the investigator pulls one thread — a complaint, a repeat deviation — through CAPA, risk management, and design as a single connected system, and watches whether your story holds. Marcus and Priya break down what changed in 2026, why training records and binders no longer equal readiness, the...

Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained 21.10.2026

Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at h...

Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained 21.10.2026

Nearly nine out of ten human-drug warning letters include at least one inadequate CAPA response. Your corrective action plan is the single most rejected document in FDA enforcement — and it's not for lack of effort. Marcus and Priya count down the five CAPA effectiveness failures that keep quality teams in warning-letter territory: fixing the event instead of the system, root causes that stop at h...

OOS Investigation Explained: Phase 1 vs Phase 2 (21 CFR 211.192) 19.10.2026

An out-of-specification result lands on your desk — and one wrong decision in the next hour can manufacture the evidence for your own warning letter. Marcus and Priya break down the two-phase OOS investigation step by step: Phase 1, the laboratory investigation, and Phase 2, the full-scale investigation, under 21 CFR 211.192 — from the Barr Labs decision to the retest rules to what to do on Monday...

ALCOA+ Explained: The 9 Data Integrity Principles FDA Actually Cites 14.10.2026

When an FDA investigator stops trusting your data, the inspection is over — because if the records can't be trusted, nothing built on them can be. Marcus and Priya break down all nine ALCOA+ principles — Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available — what investigators actually find when each one is missing, and the Monday-morning fixes that...

Top 10 FDA 483 Observations in 2026 (and How to Avoid Each One) 12.10.2026

Every year, FDA investigators write thousands of 483 observations — and almost every one was avoidable. Marcus and Priya count down the ten most-cited observations in drug manufacturing for 2026, what investigators are actually finding, and exactly how to keep your site off the list. • The #1 most-cited observation — and why it explains the other nine • Data integrity: the fastest-growing citation...

Quality Debt: The Hidden Liability Inside Pharmaceutical Quality Systems 07.10.2026

Every shortcut, deferred CAPA, and "we'll fix it later" is a loan — and quality debt charges interest. Repeat deviations, findings, and warning letters are just the payments coming due. • What quality debt is and how it silently accumulates • The interest payments: repeat deviations and FDA findings • Paying it down without stopping the line • Preventing new debt while clearing the old New episode...

The Hidden Cost of Poor Quality: The Business Impact Beyond Recalls 05.10.2026

Recalls make the headlines. But the real cost of poor quality never makes the press release — it hides in rework, investigations, remediation, and the launches that never happen. • The costs nobody puts on the recall announcement • Rework, investigations, and remediation: the real math • How poor quality taxes every future product launch • Making the business case for quality investment New episod...

Why CAPA Doesn't Fix Culture: Are We Treating Symptoms Instead of Systems? 30.09.2026

A CAPA can address a deviation. But can a CAPA change the conditions that allowed the deviation to happen? In this episode of The GMP Insider , we explore why organizations sometimes continue opening CAPAs for recurring problems without addressing deeper organizational factors. We examine five areas that can determine whether corrective action creates lasting improvement: Leadership behavior — Wha...

Compliance vs. Effectiveness vs. Sustainability: Is Your Quality System Really Healthy? 28.09.2026

A Quality System can pass an audit and still have weaknesses hiding underneath. That's because compliance, effectiveness, and sustainability are not the same thing. In this episode of The GMP Insider , we examine what it really means for a pharmaceutical Quality System to be healthy. Compliance asks: Are we meeting the requirements? Effectiveness asks: Are our controls actually working? Sustainabi...

When a Green Dashboard Lies: The Quality Signals Your Metrics Miss 23.09.2026

What if your Quality dashboard is telling you everything is fine—but your Quality System is telling a different story? In pharmaceutical Quality, metrics are essential. But metrics can also create a false sense of confidence when organizations focus on what is easy to measure rather than what truly reflects Quality System health. In this episode of The GMP Insider , we explore the hidden risks beh...

When Quality Has to Say No: The Quality Decision Nobody Wants to Make 21.09.2026

In pharmaceutical Quality, some decisions are difficult not because the science is unclear, but because the consequences of the decision are significant. A batch may be under production pressure. A manufacturing schedule may be at risk. Leadership may be asking for a decision. The available data may not provide complete certainty. And Quality still has to decide. This episode of The GMP Insider ex...

Ethics by Design: Building Trustworthy AI in Pharmaceutical Quality 13.09.2026

AI governance in the pharmaceutical industry cannot begin after deployment. By that point, critical decisions about data, accountability, human oversight, transparency, risk, and system behavior have already been embedded into the technology. So the better question is: What if ethics were designed into AI from the beginning? In this episode of The GMP Insider , we explore the concept of Ethics by...

Big Pharma vs. Small Pharma: How Culture Shapes a QA Career 13.09.2026

What is it really like to work in Quality Assurance at a large pharmaceutical company compared with a smaller organization? The answer goes far beyond company size. In this episode of The GMP Insider , we explore how Big Pharma and Small Pharma can develop very different professional skills, experiences, and perspectives—and why Quality Culture often matters more than organizational scale . Big Ph...

Quality Is Love in Action: Someone Cared Enough to Protect a Stranger 13.09.2026

What if the deepest meaning of Pharmaceutical Quality isn't compliance? What if it's caring? Every SOP written, every deviation investigated, every batch reviewed, and every quality decision made represents something bigger than a regulatory requirement. It represents a person who cared enough to do the work right. In this episode of The GMP Insider , we explore the human side of pharmaceutical qu...

Why Great QA Leaders Sleep Well After Difficult Decisions 13.09.2026

Some of the hardest decisions in Pharmaceutical Quality are not difficult because the answer is unclear. They're difficult because the right answer isn't necessarily the popular one. A Quality Leader may have to say no. They may have to escalate an uncomfortable issue. They may have to challenge production pressure. They may have to make a decision that creates short-term frustration but protects...

The Most Dangerous Day in Quality: When People Stop Asking Questions 13.09.2026

The most dangerous day in Pharmaceutical Quality isn't necessarily the day an inspector arrives. It may be the day people stop asking questions. A Quality System can appear completely compliant while a much deeper problem develops beneath the surface. SOPs are followed. CAPAs are closed. Metrics are green. Dashboards look perfect. But if people have stopped challenging assumptions, identifying ris...

Nobody Gets Promoted for Closing 500 CAPAs: Why Trusted Judgment Builds Quality Leaders 23.08.2026

In Quality Assurance, we often measure success through activity. How many CAPAs were closed? How many deviations were completed? How many investigations were approved? Those metrics are important. But they don't tell the complete story of leadership. In this episode of The GMP Insider , we explore a critical transition in every Quality Assurance career: the shift from being valued for execution to...

Escucha el podcast The GMP Insider en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos